Hypothermia for Eligible Infants with HIE
Within 6 hours of birth, eligible infants will undergo whole body cooling therapy to achieve and maintain an esophageal temperature of 33.5°C. The total period of cooling will be 72 hours. Upon completion of 72 hours of body cooling, infants will be gradually
re-warmed over a 6-hour period. The Blanketrol II Hyper/Hypothermia System, (manufactured by Cincinnati Sub-Zero), servo-controlled to the infant’s esophageal temperature will be used for this thermoregulation. The Blanketrol system is FDA approved for pediatric use and is currently in use in pediatric institutions as a hypothermia device for intra-operative cooling, febrile and sickle cell patients, and as a hyperthermia device for cold injury patients.
re-warmed over a 6-hour period. The Blanketrol II Hyper/Hypothermia System, (manufactured by Cincinnati Sub-Zero), servo-controlled to the infant’s esophageal temperature will be used for this thermoregulation. The Blanketrol system is FDA approved for pediatric use and is currently in use in pediatric institutions as a hypothermia device for intra-operative cooling, febrile and sickle cell patients, and as a hyperthermia device for cold injury patients.
Overview of the Blanketrol II Hyper/Hypothermia System
|
Preparation Prior to Initiation of Body Cooling
|
Cooling the Infant
|
Monitoring Temperatures During Body Cooling
|
Rewarming of Infants Following Body Cooling
|
Conclusion of Blanketrol II Use
|
Troubleshooting
Rare Need to Operate in the Manual Control Mode |